IMMP Soars 1646% as IOVA, LITE Lead Post-EPS Revision Surge
Immutep (IMMP) skyrocketed 1646.2% to $4.54 after its next-year EPS growth estimate hit 25.5%, detected on September 27. Iovance Biotherapeutics (IOVA) jumped 31.8% to $14.23 following a $55 million revenue guidance raise, while Lumentum (LITE) gained 13.5% to $1045.78 as its EPS growth outlook reached 57.6%. These moves highlight the outsized impact of earnings estimate revisions, particularly in healthcare and technology.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| IMMP | Healthcare | 2026-09-27 | N/A | +1646.2% |
| IOVA | Healthcare | 2026-09-24 | N/A | +31.8% |
| LITE | Technology | 2026-09-28 | N/A | +13.5% |
| LUXE | Consumer Cyclical | 2026-09-24 | +162.6pp | +8.9% |
| AMAT | Technology | 2026-09-28 | N/A | +8.7% |
Why did IMMP stock jump in October 2026?
IMMP jumped 1646.2% (from $0.26 to $4.54) since being detected on September 27, driven by a 25.5% next-year EPS growth estimate.
The micro-cap healthcare stock likely benefited from sector-wide momentum in biotechnology, as investors rotated into speculative names with improving earnings prospects. With no company-specific news, the dramatic move underscores how low-priced equities can amplify gains from estimate revisions, especially when liquidity is thin.
IMMP EPS revision history → · Screener snapshot from 2026-09-27 →
FAQ: IMMP
Why did IMMP stock jump?
IMMP surged 1646.2% to $4.54 after its next-year EPS growth estimate was revised to 25.5%, detected on September 27, 2026.
Is IMMP a buy after the rally?
With a 1646% gain and no recent earnings news, IMMP's valuation is highly speculative; investors should weigh the 25.5% EPS growth estimate against the lack of fundamental catalysts.
What is IMMP's EPS growth estimate?
IMMP's current EPS growth estimate for next year stands at 25.5%, which triggered the EPS revision screener on September 27, 2026.
Why did IOVA stock jump in October 2026?
IOVA stock surged 31.8% (from $10.80 to $14.23) after analysts raised its next-year EPS growth estimate to 52.0% on September 24.
The rally was reinforced on September 29 when Iovance raised its FY2026 revenue outlook to $410–$420 million, up from $350–$370 million, citing record Q2 product revenue of $99.3 million and strong demand for Amtagvi and Proleukin. The revised midpoint of $415 million exceeded consensus of $402.8 million, signaling accelerating commercial momentum. The company also expanded its authorized treatment center network to nearly 100 locations, supporting future growth.
IOVA EPS revision history → · Screener snapshot from 2026-09-24 →
FAQ: IOVA
Why did IOVA stock jump?
IOVA jumped 31.8% to $14.23 after its next-year EPS growth estimate was revised to 52.0% on September 24, and on September 29 the company raised FY2026 revenue guidance to $410–$420 million, beating consensus.
What caused IOVA's surge?
IOVA surged after raising FY2026 revenue guidance by $55 million at the midpoint, driven by record Q2 product revenue of $99.3 million and expanding patient demand for its cancer therapies.
Is IOVA a buy after the rally?
IOVA's strong revenue outlook and 52.0% EPS growth estimate suggest continued momentum, but investors should consider the stock's 31.8% run-up and upcoming Q3 results in November.
Why did LITE stock jump in October 2026?
LITE stock climbed 13.5% (from $921.32 to $1045.78) after its next-year EPS growth estimate was set at 57.6% on September 28.
The gain came amid a broader semiconductor and technology rally, supported by positive analyst actions in the sector, including an upgrade of Target and downgrade of Moderna that highlighted rotation into tech. Lumentum's strong earnings growth outlook reflects robust demand for its optical components used in AI and data center infrastructure.
LITE EPS revision history → · Screener snapshot from 2026-09-28 →
FAQ: LITE
Why did LITE stock jump?
LITE jumped 13.5% to $1045.78 after its next-year EPS growth estimate reached 57.6%, detected on September 28, 2026, amid a sector-wide tech rally.
What is LITE's EPS growth estimate?
LITE's current EPS growth estimate for next year is 57.6%, which triggered the EPS revision screener on September 28, 2026.
Is LITE a buy after the rally?
LITE's 57.6% EPS growth estimate and exposure to AI-driven optical demand support a bullish case, but the stock's 13.5% gain may warrant caution on valuation.
Why did LUXE stock jump in October 2026?
LUXE stock rose 8.9% (from $9.18 to $10.00) since September 24, when its next-year EPS growth estimate was revised upward to 2281.3%, a 162.6 percentage point increase.
The consumer cyclical company likely benefited from improving macroeconomic sentiment, as investors bet on a resilient consumer despite no company-specific news. The massive EPS revision signals a dramatic turnaround in profitability expectations, drawing attention from momentum traders.
LUXE EPS revision history → · Screener snapshot from 2026-09-24 →
FAQ: LUXE
Why did LUXE stock jump?
LUXE gained 8.9% to $10.00 after its next-year EPS growth estimate was revised to 2281.3%, a 162.6 percentage point increase, on September 24, 2026.
What is LUXE's EPS growth estimate?
LUXE's current EPS growth estimate for next year is 2281.3%, up from 2118.8%, reflecting a massive expected earnings rebound.
Is LUXE a buy after the rally?
LUXE's extreme EPS growth estimate of 2281.3% suggests a potential turnaround, but the lack of recent news and small price gain warrant careful due diligence.
Why did AMAT stock jump in October 2026?
AMAT shares gained 8.7% (from $486.76 to $529.30) since September 28, when its next-year EPS growth estimate was set at 46.1%.
The rally was fueled by Morgan Stanley raising its 2027 revenue and EPS forecasts to $50.7 billion and $20.92, respectively, citing higher NAND demand and better margins. A partnership with KIOXIA to develop advanced memory technologies further boosted sentiment, while a sector-wide rally after Micron earnings on October 1 added momentum.
AMAT EPS revision history → · Screener snapshot from 2026-09-28 →
FAQ: AMAT
Why did AMAT stock jump?
AMAT rose 8.7% to $529.30 after its next-year EPS growth estimate was set at 46.1% on September 28, and Morgan Stanley raised its 2027 revenue and EPS forecasts, citing higher NAND demand.
What caused AMAT's surge?
AMAT surged on a combination of an upward EPS revision, Morgan Stanley's increased 2027 forecasts, a KIOXIA partnership, and a broader semiconductor rally following Micron's earnings.
Is AMAT a buy after the rally?
AMAT's 46.1% EPS growth estimate and strong analyst support make it a compelling buy, but the stock's 8.7% gain and 25% upside to Morgan Stanley's $563 target suggest moderate room for appreciation.
The dramatic gains in IMMP, IOVA, and LITE underscore the market's sensitivity to earnings estimate revisions, especially in healthcare and technology where growth expectations are rapidly repriced. As semiconductor and biotech momentum builds, investors are rewarding companies with improving profitability outlooks, though the extreme move in IMMP signals speculative excess.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →